Oncology News | pharmaphorum

News

Amgen files KRAS trailblazer sotorasib with FDA for lung can...

Amgen has filed its groundbreaking KRAS inhibiting drug sotorasib with the FDA for a group of lung cancer patients with an aggressive form of the disease.

News

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

TG Therapeutics raises funds for cancer combination drug

TG Therapeutics provided one of the highlights of the American Society of Hematology (ASH) conference earlier this month after lifting the lid on phase 3 data from its potential challenger

News

Daiichi Sankyo, AZ close on EU approval of Enhertu for breas...

Daiichi Sankyo and AstraZeneca could be just weeks away from an EU approval for their antib

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer buys NBE for €1.18bn, adding cancer ADC expertise

Boehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics, adding an antibody-drug conjugate (ADC) platform led by a drug f

News

UK hospital deploys Microsoft AI to tackle cancer backlog

Addenbrooke’s Hospital in Cambridge will be the first in the world to use an artificial intelligence tool developed by Microsoft that promises to cut the time it takes to analyse computed t

News

FDA puts Bellicum's cancer cell therapy trial on hold

The FDA has placed a clinical hold on a phase 1/2 trial of Bellicum’s cancer cell therapy BPX-601, following a patient death.

Amgen files KRAS trailblazer sotorasib with FDA for lung can...

TG Therapeutics raises funds for cancer combination drug

Daiichi Sankyo, AZ close on EU approval of Enhertu for breas...

Boehringer buys NBE for €1.18bn, adding cancer ADC expertise

UK hospital deploys Microsoft AI to tackle cancer backlog

FDA puts Bellicum's cancer cell therapy trial on hold

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks